Unknown

Dataset Information

0

Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.


ABSTRACT: Tuberculosis (TB) vaccine development has focused largely on targeting T helper type 1 (Th1) cells. However, despite inducing Th1 cells, the recombinant TB vaccine MVA85A failed to enhance protection against TB disease in humans. In recent years, Th17 cells have emerged as key players in vaccine-induced protection against TB. However, the exact cytokine and immune requirements that enable Th17-induced recall protection remain unclear. In this study, we have investigated the requirements for Th17 cell-induced recall protection against Mycobacterium tuberculosis (Mtb) challenge by utilizing a tractable adoptive transfer model in mice. We demonstrate that adoptive transfer of Mtb-specific Th17 cells into naive hosts, and upon Mtb challenge, results in Th17 recall responses that confer protection at levels similar to vaccination strategies. Importantly, although interleukin (IL)-23 is critical, IL-12 and IL-21 are dispensable for protective Th17 recall responses. Unexpectedly, we demonstrate that interferon-? (IFN-?) produced by adoptively transferred Th17 cells impairs long-lasting protective recall immunity against Mtb challenge. In contrast, CXCR5 expression is crucial for localization of Th17 cells near macrophages within well-formed B-cell follicles to mediate Mtb control. Thus, our data identify new immune characteristics that can be harnessed to improve Th17 recall responses for enhancing vaccine design against TB.

SUBMITTER: Monin L 

PROVIDER: S-EPMC4517980 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.

Monin L L   Griffiths K L KL   Slight S S   Lin Y Y   Rangel-Moreno J J   Khader S A SA  

Mucosal immunology 20150128 5


Tuberculosis (TB) vaccine development has focused largely on targeting T helper type 1 (Th1) cells. However, despite inducing Th1 cells, the recombinant TB vaccine MVA85A failed to enhance protection against TB disease in humans. In recent years, Th17 cells have emerged as key players in vaccine-induced protection against TB. However, the exact cytokine and immune requirements that enable Th17-induced recall protection remain unclear. In this study, we have investigated the requirements for Th17  ...[more]

Similar Datasets

| S-EPMC6246638 | biostudies-other
| S-EPMC5462891 | biostudies-literature
| S-EPMC7786643 | biostudies-literature
| S-EPMC9256937 | biostudies-literature
2024-09-05 | PXD038542 | Pride
| S-EPMC3898716 | biostudies-literature
| S-EPMC5695274 | biostudies-literature
| S-EPMC5951287 | biostudies-literature
| S-EPMC3392427 | biostudies-literature
| S-EPMC6003617 | biostudies-literature